CRNBC has recently received several enquiries about whether registered nurses are allowed to administer edaravone, a drug used to treat amyotrophic lateral sclerosis (ALS) that has not been approved by Health Canada.
Based on a preliminary analysis, CRNBC has not identified any regulatory barriers under the Nurses (Registered) and Nurse Practitioners Regulation that would prevent registered nurses from administering edaravone. However, nurses are reminded that they must meet both CRNBC standards and their organizational requirements to administer edaravone.
Registered nurses require a client-specific order to administer edaravone intravenously.
Registered nurses administering edaravone are expected to meet the applicable CRNBC standards of practice, including the CRNBC Professional Standards, Standards for Acting with Client-specific Orders, and Medication Administration practice standard, and to comply with organizational policies when administering this drug.
In addition, CRNBC is doing further policy work that will guide nurses in the future who wish to carry out activities with drugs that are not yet approved by Health Canada. RNs will be expected to work within any additional standards, limits and conditions that CRNBC sets.
Email firstname.lastname@example.org if you have questions.
Please note this announcement has been updated to clarify nurses' responsibility for meeting all their organizational requirements before administering edaravone.